Sökning: WFRF:(Ejlertsen Bent) >
Leukocyte nadir as ...
Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1
-
- Poikonen-Saksela, Paula (författare)
- Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.
-
- Lindman, Henrik (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Sverrisdottir, Asgerdur (författare)
- Sodersjukhuset, Dept Oncol, Stocholm, Sweden.;Landspitali Univ Hosp, Dept Oncol, Reykjavik, Iceland.
-
visa fler...
-
- Edlund, Per (författare)
- Gävle Cent Hosp, Dept Oncol, Gävle, Sweden.
-
- Villman, Kenneth (författare)
- Örebro Univ Hosp, Dept Oncol, Örebro, Sweden.
-
- Nittby, Lena Tennvall (författare)
- Skane Univ Hosp, Dept Oncol, Malmö, Sweden.
-
- Cold, Soren (författare)
- Odense Univ Hosp, Dept Oncol, Odense, Denmark.
-
- Bechmann, Troels (författare)
- Hosp South West Jutland, Dept Oncol, Esbjerg, Denmark.;Vejle Hosp, Dept Oncol, Vejle, Denmark.
-
- Stenbygaard, Lars (författare)
- Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark.
-
- Ejlertsen, Bent (författare)
- Rigshosp, Dept Oncol, Copenhagen, Denmark.
-
- Andersson, Michael (författare)
- Rigshosp, Dept Oncol, Copenhagen, Denmark.
-
- Blomqvist, Carl (författare)
- Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.;Örebro Univ Hosp, Dept Oncol, Örebro, Sweden.
-
- Bergh, Jonas (författare)
- Karolinska Institutet
-
- Ahlgren, Johan (författare)
- Gävle Cent Hosp, Dept Oncol, Gävle, Sweden.
-
visa färre...
-
Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland;Univ Helsinki, Helsinki, Finland. Experimentell och klinisk onkologi (creator_code:org_t)
- Informa UK Limited, 2020
- 2020
- Engelska.
-
Ingår i: Acta Oncologica. - : Informa UK Limited. - 0284-186X .- 1651-226X. ; 59:7, s. 825-832
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Retrospective studies have suggested that chemotherapy-induced leukopenia is associated with improved recurrence-free or overall survival. The SBG 2000-1 trial was designed to verify the favorable prognosis associated with chemotherapy-induced leukopenia in early breast cancer. Patients not experiencing chemotherapy-induced leukopenia were randomized into standard dosed or individually escalated chemotherapy doses based on the grade of leukopenia after a first standard dose.Patients and methods: 1452 women in Sweden and Denmark with operable node-positive or high-risk node-negative breast cancer aged 18-60 years were recruited to participate in this trial. Participants received a first FEC cycle at standard doses (600/60/600 mg/m(2)). Patients (n = 1052) with nadir leukopenia grade 0-2 after the first cycle were randomized between either 6 standard FEC or 6 tailored FEC courses with doses of epirubicin and cyclophosphamide escalated during courses 2 and 3 and thereafter aimed at achieving grade 3 leukopenia. Patients with nadir leukopenia grade 3-4 after the first course continued treatment with standard FEC. Results of the randomized comparison has been published previously. The present study focuses on chemotherapy-induced leukopenia as a covariable with outcome in randomized and non-randomized patients. The prognostic value of leukopenia after course 3, was studied in a Cox model adjusted for cumulative doses of epirubicin and cyclophosphamide. The association of chemotherapy-induced leukopenia with prognosis was a preplanned secondary endpoint for this trial.Results: The eight-year distant disease-free survival was 73%, 77%, 78% and 83% for patients with leucocyte nadir grade 0, 1, 2 and 3-4, respectively. Higher degree of leukopenia was highly significantly associated to improved distant disease-free survival (HR 0.84, 95% CI 0.74-0.96, p = .008) and overall survival (HR 0.87 (0.76-0.99, p = .032).Conclusion: This prospective study confirms that chemotherapy-induced leukopenia is a covariable with outcome in primary breast cancer, even after adjustment for chemotherapy doses.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- NCT03888677
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Poikonen-Saksela ...
-
Lindman, Henrik
-
Sverrisdottir, A ...
-
Edlund, Per
-
Villman, Kenneth
-
Nittby, Lena Ten ...
-
visa fler...
-
Cold, Soren
-
Bechmann, Troels
-
Stenbygaard, Lar ...
-
Ejlertsen, Bent
-
Andersson, Micha ...
-
Blomqvist, Carl
-
Bergh, Jonas
-
Ahlgren, Johan
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Acta Oncologica
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet